Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo

Glaucoma Clinical Trial

Official title:

Relationship Between Intraocular Pressure Fluctuation and Retinal Ganglion Cell Function in Eyes Receiving Latanoprost 0.005% Versus Placebo

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01042665
• Other study ID #: 20057259
• Status: Completed
• Phase: N/A
• First received: January 4, 2010
• Last updated: March 27, 2014
• Start date: February 2006
• Est. completion date: December 2009

Study information

• Verified date: March 2014
• Source: University of Miami
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this investigation is to evaluate the relationship between IOP fluctuation, RGC dysfunction, and optic nerve and retinal nerve fiber layer (RNFL) thickness changes in patients with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.

Description:

It has been hypothesized that intraocular (IOP) variability is an independent risk factor for the progression of glaucoma. IOP variability includes 24 hour IOP fluctuation during the waking period (diurnal fluctuation) and sleep period (nocturnal fluctuation) as well as longitudinal IOP variability measured in the diurnal period over the course of multiple office visits.

Latanoprost has been clinically used to lower eye pressure in glaucoma and ocular hypertension for almost 10 years. Latanoprost 0.005% has been demonstrated to provide superior ocular hypotensive efficacy compared with timolol 0.5% in pivotal phase 3 clinical trials (Alm et al. 1995; Camras 1996).

The Pattern Electroretinogram (PERG) is a non-invasive technology that objectively measures the retinal ganglion cell (RGC) function (Porciatti and Ventura 2004). A recent study has demonstrated that the RGC function can be improved following IOP reduction in glaucomatous eyes with early visual field defects (Ventura and Porciatti 2005).

The purpose of this investigation is to evaluate the relationship between IOP fluctuation, RGC dysfunction, and optic nerve and retinal nerve fiber layer (RNFL) thickness changes in patients with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

Inclusion Criteria - OHT:

• Ocular hypertension defined as an IOP = 24 mm Hg and = 32 mm Hg in one eye and IOP = 22 mm Hg and = 32 mm Hg in the fellow eye

• Normal optic disc

• Normal visual field defined as follows:

• Mean Deviation (MD) or Pattern Standard Deviation (PSD) of p>5%

• Normal Glaucoma Hemifield Test (GHT)

• Reliable visual field exam (less than 33% false positives or false negatives, and less than 20% fixation losses)

Inclusion Criteria - POAG:

• Glaucomatous visual field loss defined as a CPSD (p < 0.05), or GHT (p < 1%) outside normal limits with consistent with ONH or NFL defect

• Early visual field loss defined as MD = -6.0 dB

• Untreated IOP = 32 mmHg

• ONH or NFL defect defined as either inter-eye CDR asymmetry > 0.2, rim thinning or notching, or NFL bundle defect visible on slitlamp biomicroscopy and stereo color fundus photography

Exclusion Criteria:

Exclusion Criteria - OHT:

• Best-corrected visual acuity less than 20/40 either eye

• Abnormal or unreliable VF

• Untreated IOP > 32 mmHg

• Age < 18 or >85 years

• Refractive error of > +3.00 D or < -7.00 D

• Previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation

• Need for chronic ocular or systemic corticosteroid use

• Narrow/closed angle (gonioscopy must show 75% or more of the angle to be Grade 2 or more by Shaffer's grading system)

• Diabetic retinopathy

• Other diseases that may cause VF loss or optic disc abnormalities

• Life-threatening or debilitating illness making it unlikely patient could successfully complete the study

• Inability to clinically view or photograph the optic discs due to media opacity or poorly dilating pupil

• Refusal of informed consent or of commitment to the full length of the study

• Contraindication to latanoprost or placebo vehicle

Exclusion criteria - POAG:

• Best-corrected visual acuity less than 20/40

• Untreated IOP > 32 mmHg

• Age < 18 or >85 years

• Refractive error of > +3.00 D or < -7.00 D

• Previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation

• Diabetic retinopathy

• Other diseases that may cause VF loss or optic disc abnormalities

• Inability to clinically view or photograph the optic discs due to media opacity or poorly dilating pupil

• Inability to perform reliably on automated VF testing

• Life-threatening or debilitating illness making it unlikely patient could successfully complete the study.

• Refusal of informed consent or of commitment to the full length of the study

• Contraindication to latanoprost or placebo vehicle

Study Design

Observational Model: Case-Crossover, Time Perspective: Prospective

Related Conditions & MeSH terms

• Glaucoma

Intervention

Drug:
• latanoprost 0.005%
Active comparator
• Placebo
Placebo comparator

Locations

Country	Name	City	State
United States	University of Miami Bascom Palmer Eye Institute	Palm Beach Gardens	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Miami	Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evidence of impact of intraocular (IOP) reduction on retinal ganglion cell (RGC) function	RGC function is evaluated by pattern electroretinogram optimized for glaucoma (PERGLA)	8 weeks	No